Condition: Healthy · Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
The aim of this study is to investigate the safety and tolerability of HB0034 in healthy subjects following a single dose or multiple dose.
This description comes directly from the study's public registry record.
Yuan Tang · +86 15821321563 · yuan.tang@huaota.com
Qiaoxia Qian · +86 18555690860 · qiaoxia.qian@huaota.com
Always discuss trial participation with your own doctor first.
| Central Hospital affiliated to Shandong First Medical University | Jinan, Shandong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06716151